FLOWSERVE CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that FLOWSERVE CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $0 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $0 | Feb 20, 2024 |
| FY2021 | Dec 31, 2020 | $0 | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $0 | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $0 | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $0 | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $0 | Feb 20, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.73B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $4.56B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $4.32B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $3.62B | Feb 26, 2025 |
| FY2021 | Dec 31, 2021 | $919.50M | Feb 23, 2022 |
| FY2021 | Sep 30, 2021 | $866.10M | Feb 23, 2022 |
| FY2021 | Jun 30, 2021 | $898.20M | Feb 23, 2022 |
| FY2021 | Mar 31, 2021 | $857.30M | Feb 23, 2022 |
| FY2021 | Dec 31, 2020 | $985.30M | Feb 23, 2022 |
| FY2021 | Sep 30, 2020 | $924.30M | Feb 23, 2022 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.03B | Feb 28, 2018 |
| FY2017 | Sep 30, 2017 | $883.40M | Feb 28, 2018 |
| FY2017 | Jun 30, 2017 | $877.10M | Feb 28, 2018 |
| FY2017 | Mar 31, 2017 | $866.30M | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $1.07B | Feb 28, 2018 |
| FY2017 | Sep 30, 2016 | $945.90M | Feb 28, 2018 |
| FY2017 | Jun 30, 2016 | $1.03B | Feb 28, 2018 |
| FY2017 | Mar 31, 2016 | $946.20M | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $1.29B | Aug 11, 2017 |
| FY2016 | Sep 30, 2015 | $1.09B | Aug 11, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.58B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.43B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.28B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $994.30M | Feb 26, 2025 |
| FY2021 | Dec 31, 2021 | $267.10M | Feb 23, 2022 |
| FY2021 | Sep 30, 2021 | $253.50M | Feb 23, 2022 |
| FY2021 | Jun 30, 2021 | $278.20M | Feb 23, 2022 |
| FY2021 | Mar 31, 2021 | $250.90M | Feb 23, 2022 |
| FY2021 | Dec 31, 2020 | $295.40M | Feb 23, 2022 |
| FY2021 | Sep 30, 2020 | $285.20M | Feb 23, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $346.25M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $282.76M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $186.74M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $188.69M | Feb 26, 2025 |
| FY2021 | Dec 31, 2021 | $16.70M | Feb 23, 2022 |
| FY2021 | Sep 30, 2021 | $49.80M | Feb 23, 2022 |
| FY2021 | Jun 30, 2021 | $45.40M | Feb 23, 2022 |
| FY2021 | Mar 31, 2021 | $14.10M | Feb 23, 2022 |
| FY2021 | Dec 31, 2020 | $56.05M | Feb 23, 2022 |
| FY2021 | Sep 30, 2020 | $56.10M | Feb 23, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $399.92M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $462.28M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $333.55M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $197.22M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $270.76M | Feb 20, 2024 |
| FY2021 | Dec 31, 2020 | $250.28M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $386.62M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $227.70M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $341.14M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $276.68M | Feb 20, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.10M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $69.90M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $48.70M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $39.90M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $34.20M | Feb 20, 2024 |
| FY2021 | Dec 31, 2020 | $36.10M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $42.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $39.60M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $38.60M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $42.80M | Feb 20, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.06B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $978.04M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $961.17M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $815.55M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $797.08M | Feb 20, 2024 |
| FY2021 | Dec 31, 2020 | $878.25M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $913.20M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $966.58M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $901.73M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $965.38M | Feb 20, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $505.88M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $425.31M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $325.77M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | ($40.01M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $250.12M | Feb 20, 2024 |
| FY2021 | Dec 31, 2020 | $310.54M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $324.10M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $190.83M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $311.07M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $240.48M | Feb 20, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.71B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $5.50B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $5.11B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $4.79B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $4.75B | Feb 20, 2024 |
| FY2021 | Dec 31, 2020 | $5.31B | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $4.94B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $4.65B | Feb 23, 2021 |
| FY2018 | Jan 1, 2018 | $4.84B | Feb 20, 2019 |
| FY2019 | Dec 31, 2017 | $4.91B | Feb 18, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $3.03B | Feb 17, 2015 |
| FY2013 | Dec 31, 2013 | $3.16B | Feb 18, 2014 |
| FY2012 | Dec 31, 2012 | $2.92B | Feb 21, 2013 |
| FY2012 | Dec 31, 2011 | $2.34B | Feb 21, 2013 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.19B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.01B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $1.94B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $1.82B | Feb 20, 2024 |
| FY2021 | Dec 31, 2021 | $1.80B | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $1.73B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $1.75B | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $1.64B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $1.65B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $1.62B | Feb 28, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.39B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.29B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.18B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.17B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $1.20B | Feb 20, 2024 |
| FY2021 | Dec 31, 2020 | $1.22B | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $1.19B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $1.20B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $1.22B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $1.21B | Feb 20, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.26B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $4.03B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $3.85B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $3.77B | Feb 20, 2024 |
| FY2021 | Dec 31, 2021 | $3.69B | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $3.67B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $3.65B | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $3.54B | Feb 18, 2020 |
| FY2018 | Jan 1, 2018 | $3.52B | Feb 20, 2019 |
| FY2018 | Dec 31, 2017 | $3.50B | Feb 20, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $760.18M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $675.44M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $545.68M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $434.97M | Feb 20, 2024 |
| FY2021 | Dec 31, 2021 | $658.45M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $1.10B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $670.98M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $619.68M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $703.45M | Feb 20, 2019 |
| FY2018 | Dec 31, 2016 | $367.16M | Feb 20, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.58B | Feb 17, 2026 |
| FY2024 | Dec 31, 2024 | $1.50B | Feb 26, 2025 |
| FY2023 | Dec 31, 2023 | $1.23B | Feb 20, 2024 |
| FY2021 | Dec 31, 2022 | $1.27B | Mar 7, 2023 |
| FY2021 | Dec 31, 2021 | $1.30B | Feb 23, 2022 |
| FY2020 | Dec 31, 2020 | $1.73B | Feb 23, 2021 |
| FY2019 | Dec 31, 2019 | $1.38B | Feb 18, 2020 |
| FY2018 | Dec 31, 2018 | $1.48B | Feb 20, 2019 |
| FY2017 | Dec 31, 2017 | $1.58B | Feb 28, 2018 |
| FY2016 | Dec 31, 2016 | $1.57B | Aug 11, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 26, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Feb 23, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Feb 23, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 26, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Feb 23, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Feb 23, 2022 |